Works by Shapiro, Geoffrey I.

Results: 53
    1
    2
    3

    BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial.

    Published in:
    Cancers, 2022, v. 14, n. 17, p. 4079, doi. 10.3390/cancers14174079
    By:
    • Hilton, John;
    • Cristea, Mihaela;
    • Postel-Vinay, Sophie;
    • Baldini, Capucine;
    • Voskoboynik, Mark;
    • Edenfield, William;
    • Shapiro, Geoffrey I.;
    • Cheng, Michael L.;
    • Vuky, Jacqueline;
    • Corr, Bradley;
    • Das, Sharmila;
    • Apfel, Abraham;
    • Xu, Ke;
    • Kozicki, Martin;
    • Ünsal-Kaçmaz, Keziban;
    • Hammell, Amy;
    • Wang, Guan;
    • Ravindran, Palanikumar;
    • Kollia, Georgia;
    • Esposito, Oriana
    Publication type:
    Article
    4
    5

    Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.

    Published in:
    2023
    By:
    • Curigliano, Giuseppe;
    • Shapiro, Geoffrey I.;
    • Kristeleit, Rebecca S.;
    • Abdul Razak, Albiruni R.;
    • Leong, Stephen;
    • Alsina, Maria;
    • Giordano, Antonio;
    • Gelmon, Karen A.;
    • Stringer-Reasor, Erica;
    • Vaishampayan, Ulka N.;
    • Middleton, Mark;
    • Olszanski, Anthony J.;
    • Rugo, Hope S.;
    • Kern, Kenneth A.;
    • Pathan, Nuzhat;
    • Perea, Rachelle;
    • Pierce, Kristen J.;
    • Mutka, Sarah C.;
    • Wainberg, Zev A.
    Publication type:
    Correction Notice
    6

    A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.

    Published in:
    2023
    By:
    • Curigliano, Giuseppe;
    • Shapiro, Geoffrey I.;
    • Kristeleit, Rebecca S.;
    • Abdul Razak, Albiruni R.;
    • Leong, Stephen;
    • Alsina, Maria;
    • Giordano, Antonio;
    • Gelmon, Karen A.;
    • Stringer-Reasor, Erica;
    • Vaishampayan, Ulka N.;
    • Middleton, Mark;
    • Olszanski, Anthony J.;
    • Rugo, Hope S.;
    • Kern, Kenneth A.;
    • Pathan, Nuzhat;
    • Perea, Rachelle;
    • Pierce, Kristen J.;
    • Mutka, Sarah C.;
    • Wainberg, Zev A.
    Publication type:
    journal article
    7
    8
    9

    Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.

    Published in:
    2017
    By:
    • Mita, Monica M;
    • Mita, Alain C;
    • Moseley, Jennifer L;
    • Poon, Jennifer;
    • Small, Karen A;
    • Jou, Ying-Ming;
    • Kirschmeier, Paul;
    • Zhang, Da;
    • Zhu, Yali;
    • Statkevich, Paul;
    • Sankhala, Kamelesh K;
    • Sarantopoulos, John;
    • Cleary, James M;
    • Chirieac, Lucian R;
    • Rodig, Scott J;
    • Bannerji, Rajat;
    • Shapiro, Geoffrey I
    Publication type:
    journal article
    10
    11
    12

    Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.

    Published in:
    NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00406-0
    By:
    • Telli, Melinda L.;
    • Tolaney, Sara M.;
    • Shapiro, Geoffrey I.;
    • Middleton, Mark;
    • Lord, Simon R.;
    • Arkenau, Hendrik Tobias;
    • Tutt, Andrew;
    • Abramson, Vandana;
    • Dean, Emma;
    • Haddad, Tufia C.;
    • Wesolowski, Robert;
    • Ferrer-Playan, Jordi;
    • Goddemeier, Thomas;
    • Grombacher, Thomas;
    • Dong, Jennifer;
    • Fleuranceau-Morel, Patricia;
    • Diaz-Padilla, Ivan;
    • Plummer, Ruth
    Publication type:
    Article
    13
    14

    MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-024-55316-5
    By:
    • Gounder, Mrinal;
    • Johnson, Melissa;
    • Heist, Rebecca S.;
    • Shapiro, Geoffrey I.;
    • Postel-Vinay, Sophie;
    • Wilson, Frederick H.;
    • Garralda, Elena;
    • Wulf, Gerburg;
    • Almon, Caroline;
    • Nabhan, Salah;
    • Aguado-Fraile, Elia;
    • He, Peng;
    • Romagnoli, Mathilde;
    • Hossain, Mohammad;
    • Narayanaswamy, Rohini;
    • Sadou-Dubourgnoux, Amel;
    • Cooper, Michael;
    • Askoxylakis, Vasileios;
    • Burris, Howard A.;
    • Tabernero, Josep
    Publication type:
    Article
    15
    16
    17
    18
    19

    Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF‐mutant solid tumors.

    Published in:
    Cancer (0008543X), 2023, v. 129, n. 12, p. 1904, doi. 10.1002/cncr.34730
    By:
    • Mooradian, Meghan J.;
    • Cleary, James M.;
    • Giobbie‐Hurder, Anita;
    • Darville, Lancia N. F.;
    • Parikh, Aparna;
    • Buchbinder, Elizabeth I.;
    • Cohen, Justine V.;
    • Lawrence, Donald P.;
    • Shapiro, Geoffrey I.;
    • Keer, Harold;
    • Chen, Helen X.;
    • Ivy, Susan Percy;
    • Smalley, Keiran S. M.;
    • Koomen, John M.;
    • Sullivan, Ryan J.
    Publication type:
    Article
    20
    21
    22
    23

    Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

    Published in:
    Nature Medicine, 2011, v. 17, n. 7, p. 875, doi. 10.1038/nm.2377
    By:
    • Johnson, Neil;
    • Yu-Chen Li;
    • Walton, Zandra E.;
    • Cheng, Katherine A.;
    • Danan Li;
    • Rodig, Scott J.;
    • Moreau, Lisa A.;
    • Unitt, Christine;
    • Bronson, Roderick T.;
    • Thomas, Huw D.;
    • Newell, David R.;
    • D'Andrea, Alan D.;
    • Curtin, Nicola J.;
    • Kwok-Kin Wong;
    • Shapiro, Geoffrey I.
    Publication type:
    Article
    24

    Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2020, v. 86, n. 6, p. 815, doi. 10.1007/s00280-020-04176-z
    By:
    • Do, Khanh T.;
    • O'Sullivan Coyne, Geraldine;
    • Hays, John L.;
    • Supko, Jeffrey G.;
    • Liu, Stephen V.;
    • Beebe, Kristin;
    • Neckers, Len;
    • Trepel, Jane B.;
    • Lee, Min-Jung;
    • Smyth, Tomoko;
    • Gannon, Courtney;
    • Hedglin, Jennifer;
    • Muzikansky, Alona;
    • Campos, Susana;
    • Lyons, John;
    • Ivy, Percy;
    • Doroshow, James H.;
    • Chen, Alice P.;
    • Shapiro, Geoffrey I.
    Publication type:
    Article
    25
    26

    The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.

    Published in:
    British Journal of Clinical Pharmacology, 2021, v. 87, n. 3, p. 1291, doi. 10.1111/bcp.14508
    By:
    • Pooler, Darcy B.;
    • Ness, Dylan B.;
    • Sarantopoulos, John;
    • Squittieri, Nicholas;
    • Ravichandran, Shoba;
    • Britten, Carolyn D.;
    • Amaravadi, Ravi K.;
    • Vaishampayan, Ulka;
    • LoRusso, Patricia;
    • Shapiro, Geoffrey I.;
    • Olszanski, Anthony J.;
    • Perez, Raymond;
    • Gutierrez, Martin;
    • O'Rourke, Mark Allen;
    • Chung, Vincent;
    • Lee, James J.;
    • Lewis, Lionel D.
    Publication type:
    Article
    27
    28
    29

    Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.

    Published in:
    Clinical Pharmacology in Drug Development, 2019, v. 8, n. 1, p. 107, doi. 10.1002/cpdd.575
    By:
    • Shapiro, Geoffrey I.;
    • Kristeleit, Rebecca S.;
    • Burris, Howard A.;
    • LoRusso, Patricia;
    • Patel, Manish R.;
    • Drew, Yvette;
    • Giordano, Heidi;
    • Maloney, Lara;
    • Watkins, Simon;
    • Goble, Sandra;
    • Jaw‐Tsai, Sarah;
    • Xiao, Jim J.
    Publication type:
    Article
    30
    31

    MUC1-C dependency in drug resistant HR+/HER2− breast cancer identifies a new target for antibody-drug conjugate treatment.

    Published in:
    NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00751-w
    By:
    • Nakashoji, Ayako;
    • Bhattacharya, Atrayee;
    • Ozawa, Hiroki;
    • Haratake, Naoki;
    • Shigeta, Keisuke;
    • Fushimi, Atsushi;
    • Yamashita, Nami;
    • Matsui, Akira;
    • Kure, Shoko;
    • Kameyama, Tomoe;
    • Takeuchi, Makoto;
    • Fukuda, Kazumasa;
    • Yokoe, Takamichi;
    • Nagayama, Aiko;
    • Hayahsida, Tetsu;
    • Kitagawa, Yuko;
    • Liu, Renyan;
    • Giordano, Antonio;
    • Jeselsohn, Rinath;
    • Shapiro, Geoffrey I.
    Publication type:
    Article
    32

    Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.

    Published in:
    Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-16344-z
    By:
    • Färkkilä, Anniina;
    • Gulhan, Doga C.;
    • Casado, Julia;
    • Jacobson, Connor A.;
    • Huy Nguyen;
    • Kochupurakkal, Bose;
    • Maliga, Zoltan;
    • Yapp, Clarence;
    • Yu-An Chen;
    • Schapiro, Denis;
    • Yinghui Zhou;
    • Graham, Julie R.;
    • Dezube, Bruce J.;
    • Munster, Pamela;
    • Santagata, Sandro;
    • Garcia, Elizabeth;
    • Rodig, Scott;
    • Lako, Ana;
    • Chowdhury, Dipanjan;
    • Shapiro, Geoffrey I.
    Publication type:
    Article
    33

    Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.

    Published in:
    Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-15315-8
    By:
    • Färkkilä, Anniina;
    • Gulhan, Doga C.;
    • Casado, Julia;
    • Jacobson, Connor A.;
    • Nguyen, Huy;
    • Kochupurakkal, Bose;
    • Maliga, Zoltan;
    • Yapp, Clarence;
    • Chen, Yu-An;
    • Schapiro, Denis;
    • Zhou, Yinghui;
    • Graham, Julie R.;
    • Dezube, Bruce J.;
    • Munster, Pamela;
    • Santagata, Sandro;
    • Garcia, Elizabeth;
    • Rodig, Scott;
    • Lako, Ana;
    • Chowdhury, Dipanjan;
    • Shapiro, Geoffrey I.
    Publication type:
    Article
    34
    35

    Early Detection of Erlotinib Treatment Response in NSCLC by 3'-Deoxy-3'-[<sup>18</sup>F]-Fluoro-L-Thymidine ([<sup>18</sup>F]FLT) Positron Emission Tomography (PET).

    Published in:
    PLoS ONE, 2008, v. 3, n. 12, p. 1, doi. 10.1371/journal.pone.0003908
    By:
    • Ullrich, Roland T.;
    • Zander, Thomas;
    • Neumaier, Bernd;
    • Koker, Mirjam;
    • Shimamura, Takeshi;
    • Waerzeggers, Yannic;
    • Borgman, Christa L.;
    • Tawadros, Samir;
    • Hongfeng Li;
    • Sos, Martin L.;
    • Backes, Heiko;
    • Shapiro, Geoffrey I.;
    • Wolf, Jürgen;
    • Jacobs, Andreas H.;
    • Thomas, Roman K.;
    • Winkeler, Alexandra
    Publication type:
    Article
    36

    Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.

    Published in:
    Oncologist, 2018, v. 23, n. 7, p. 814, doi. 10.1634/theoncologist.2017-0552
    By:
    • Rabinowits, Guilherme;
    • Lezcano, Cecilia;
    • Catalano, Paul J.;
    • McHugh, Patricia;
    • Becker, Hailey;
    • Reilly, Megan M.;
    • Huang, Julian;
    • Tyagi, Ayushi;
    • Thakuria, Manisha;
    • Bresler, Scott C.;
    • Sholl, Lynette M.;
    • Shapiro, Geoffrey I.;
    • Haddad, Robert;
    • DeCaprio, James A.
    Publication type:
    Article
    37

    A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.

    Published in:
    Oncologist, 2018, v. 23, n. 6, p. 658, doi. 10.1634/theoncologist.2017-0325
    By:
    • Tolcher, Anthony;
    • Flaherty, Keith;
    • Shapiro, Geoffrey I.;
    • Berlin, Jordan;
    • Witzig, Thomas;
    • Habermann, Thomas;
    • Bullock, Andrea;
    • Rock, Edwin;
    • Elekes, Agnes;
    • Lin, Chester;
    • Kostic, Dusan;
    • Ohi, Naoto;
    • Rasco, Drew;
    • Papadopoulos, Kyriakos P.;
    • Patnaik, Amita;
    • Smith, Lon;
    • Cote, Gregory M.
    Publication type:
    Article
    38
    39
    40
    41

    Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
    By:
    • Harding, James J.;
    • Piha-Paul, Sarina A.;
    • Shah, Ronak H.;
    • Murphy, Jessica J.;
    • Cleary, James M.;
    • Shapiro, Geoffrey I.;
    • Quinn, David I.;
    • Braña, Irene;
    • Moreno, Victor;
    • Borad, Mitesh;
    • Loi, Sherene;
    • Spanggaard, Iben;
    • Park, Haeseong;
    • Ford, James M.;
    • Arnedos, Mónica;
    • Stemmer, Salomon M.;
    • de la Fouchardiere, Christelle;
    • Fountzilas, Christos;
    • Zhang, Jie;
    • DiPrimeo, Daniel
    Publication type:
    Article
    42

    Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
    By:
    • Harding, James J.;
    • Piha-Paul, Sarina A.;
    • Shah, Ronak H.;
    • Murphy, Jessica J.;
    • Cleary, James M.;
    • Shapiro, Geoffrey I.;
    • Quinn, David I.;
    • Braña, Irene;
    • Moreno, Victor;
    • Borad, Mitesh;
    • Loi, Sherene;
    • Spanggaard, Iben;
    • Park, Haeseong;
    • Ford, James M.;
    • Arnedos, Mónica;
    • Stemmer, Salomon M.;
    • de la Fouchardiere, Christelle;
    • Fountzilas, Christos;
    • Zhang, Jie;
    • DiPrimeo, Daniel
    Publication type:
    Article
    43

    Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial.

    Published in:
    Cancer (0008543X), 2025, v. 131, n. 4, p. 1, doi. 10.1002/cncr.35755
    By:
    • Cecchini, Michael;
    • Pilat, Mary Jo;
    • Uboha, Nataliya;
    • Azad, Nilofer S.;
    • Cho, May;
    • Davis, Elizabeth J.;
    • Ahnert, Jordi Rodon;
    • Tinoco, Gabriel;
    • Shapiro, Geoffrey I.;
    • Khagi, Simon;
    • Powers, Benjamin;
    • Spencer, Kristen;
    • Groisberg, Roman;
    • Drappatz, Jan;
    • Chen, Li;
    • Das, Biswajit;
    • Bao, Xun;
    • Li, Jing;
    • Narayan, Azeet;
    • Vu, Dennis
    Publication type:
    Article
    44
    45

    A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 1, p. 163, doi. 10.1007/s10637-020-00975-6
    By:
    • Shapiro, Geoffrey I.;
    • LoRusso, Patricia;
    • Cho, Daniel C.;
    • Musib, Luna;
    • Yan, Yibing;
    • Wongchenko, Matthew;
    • Chang, Ilsung;
    • Patel, Premal;
    • Chan, Iris T.;
    • Sanabria-Bohorquez, Sandra;
    • Meng, Raymond D.;
    • Bendell, Johanna C.
    Publication type:
    Article
    46

    A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 5, p. 1483, doi. 10.1007/s10637-020-00908-3
    By:
    • Cleary, James M.;
    • Calvo, Emiliano;
    • Moreno, Victor;
    • Juric, Dejan;
    • Shapiro, Geoffrey I.;
    • Vanderwal, Carol Ann;
    • Hu, Beibei;
    • Gifford, Maryella;
    • Barch, David;
    • Roberts-Rapp, Lisa;
    • Ansell, Peter J.;
    • Xiong, Hao;
    • Ocampo, Christopher;
    • Tolcher, Anthony W.
    Publication type:
    Article
    47

    Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 2, p. 419, doi. 10.1007/s10637-019-00776-6
    By:
    • Shapiro, Geoffrey I.;
    • LoRusso, Patricia;
    • Kwak, Eunice;
    • Pandya, Susan;
    • Rudin, Charles M.;
    • Kurkjian, Carla;
    • Cleary, James M.;
    • Pilat, Mary Jo;
    • Jones, Suzanne;
    • de Crespigny, Alex;
    • Fredrickson, Jill;
    • Musib, Luna;
    • Yan, Yibing;
    • Wongchenko, Matthew;
    • Hsieh, Hsin-Ju;
    • Gates, Mary R.;
    • Chan, Iris T.;
    • Bendell, Johanna
    Publication type:
    Article
    48
    49

    A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.

    Published in:
    Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-25904-w
    By:
    • Konstantinopoulos, Panagiotis A.;
    • da Costa, Alexandre André B. A.;
    • Gulhan, Doga;
    • Lee, Elizabeth K.;
    • Cheng, Su-Chun;
    • Hendrickson, Andrea E. Wahner;
    • Kochupurakkal, Bose;
    • Kolin, David L.;
    • Kohn, Elise C.;
    • Liu, Joyce F.;
    • Stover, Elizabeth H.;
    • Curtis, Jennifer;
    • Tayob, Nabihah;
    • Polak, Madeline;
    • Chowdhury, Dipanjan;
    • Matulonis, Ursula A.;
    • Färkkilä, Anniina;
    • D'Andrea, Alan D.;
    • Shapiro, Geoffrey I.
    Publication type:
    Article
    50

    Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.

    Published in:
    Targeted Oncology, 2023, v. 18, n. 1, p. 105, doi. 10.1007/s11523-022-00931-9
    By:
    • Kollmannsberger, Christian;
    • Hurwitz, Herbert;
    • Bazhenova, Lyudmila;
    • Cho, Byoung Chul;
    • Hong, David;
    • Park, Keunchil;
    • Reckamp, Karen L.;
    • Sharma, Sunil;
    • Der-Torossian, Hirak;
    • Christensen, James G.;
    • Faltaos, Demiana;
    • Potvin, Diane;
    • Tassell, Vanessa;
    • Chao, Richard;
    • Shapiro, Geoffrey I.
    Publication type:
    Article